598890 Disclosed herein are compounds of formula (I) U1-M-U2 wherein the variables are defined in the specification the use of said compounds in the treatment of cancer specifically by sensitising a cell to an apoptotic signal. Additionally said compounds may be used for sequential or concomitant use with a pharmaceutical compound which induces an apoptotic signal such as cytarabine fludarabine 5-fluoro-2'-deoxyuridine 5 gemcitabine methotrexate bleomycin cisplatin cyclophosphamide adriamycin (d...

The invention provides SNS-595 for use in a method of treating myelodysplastic syndrome, including chronic myelomonocytic leukemia. The treatment with SNS-595 may be combined with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the treatment comprises administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

PURPOSE: A composition for treating Epstein-Barr virus-positive gastric cancer is provided to suppress proliferation of Epstein-Barr virus and to effectively treat Epstein-Barr virus-positive gastric cancer when ganciclovir and gemcitabine are combined. CONSTITUTION: A pharmaceutical composition for treating Epstein-Barr virus-positive gastric cancer contains an anti-herpes viral agent and 1 ng/ml or greater of gemcitabine. The anti-herpes viral agent is selected among ganciclovir acyclovir penc...

The present invention relates to combinations of N-[2-(2,1,3-benzothiadiazol-5- ylamino)-6-(2,6-dichlorophenyl) pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea and cytarabine and their use for treating AML or CML.

The present invention relates to combinations of N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl) pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea and cytarabine and their use for treating AML or CML.

The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 1-beta-D-arabinofuranosylcytosine (cytarabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.

Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical ...

The disclosure relates to compounds and compositions for bone formation fracture treatment bone grafting bone fusion cartilage maintenance and repair and methods related thereto. In certain embodiments the disclosure relates to compositions comprising one or more compound(s) disclosed herein such as clotrimazole honokiol magnolol tacrolimus pimecrolimus sirolimus everolimus temsirolimus spironolactone fluticasone fluticasone propionate fluticasone furoate linezolid telmisartan chlorambucil retin...